Pulmonx Q1 2024 GAAP EPS $(0.36) Beats $(0.46) Estimate, Sales $18.854M Beat $17.893M Estimate

5/1/24 4:39:22 PM ET

Medical/Dental Instruments

Health Care

Get the next $LUNG alert in real time by email

Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $18.854 million which beat the analyst consensus estimate of $17.893 million by 5.37 percent. This is a 29.71 percent increase over sales of $14.535 million the same period last year.

Get the next $LUNG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LUNG

Date	Price Target	Rating	Analyst
6/4/2024	$12.00	Buy	Lake Street
2/23/2024	$16.00 → $14.00	Overweight → Equal Weight	Wells Fargo
9/5/2023	$18.00	Buy	Craig Hallum
2/27/2023	$10.00 → $15.00	Equal Weight → Overweight	Wells Fargo
1/3/2023	$8.00	Neutral → Underperform	BofA Securities
12/12/2022	$14.00 → $10.00	Neutral → Buy	Citigroup
7/11/2022	$23.00 → $19.00	Buy → Neutral	Citigroup
3/2/2022	$28.00	Neutral	BofA Securities

More analyst ratings

$LUNG
Financials

Live finance-specific insights

Pulmonx Reports Third Quarter 2024 Financial Results
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights Achieved worldwide revenue of $20.4 million in the third quarter of 2024, a 15% increase over the same period last yearDelivered $13.8 million in U.S. revenue in the third quarter of 2024, representing 17% year-over-year growthRealized gross margin of 74% in the third quarter of 2024Added 15 new Zephyr® Valve U.S. treatment centers in the third quarter of 20246-month data from the AeriSeal® CONV
10/30/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care
Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chron
10/16/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care
Pulmonx Reports Second Quarter 2024 Financial Results
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $13.9 million in U.S. revenue in the second quarter of 2024, representing 26% year-over-year growthRealized gross margin of 74% in the second quarter of 2024Added 17 new Zephyr® Valve U.S. treatment centers in the sec
7/31/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him
4/2/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of
2/21/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors
LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir
12/11/23 9:00:00 AM ET
$HNST
$LUNG
Catalog/Specialty Distribution
Consumer Discretionary
Medical/Dental Instruments
Health Care

Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephy
11/20/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care
Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and trea
11/7/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care
Pulmonx to Present at the Stifel 2024 Healthcare Conference
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial
11/5/24 4:05:00 PM ET
$LUNG
Medical/Dental Instruments
Health Care

Pulmonx Q1 2024 GAAP EPS $(0.36) Beats $(0.46) Estimate, Sales $18.854M Beat $17.893M Estimate

Chat with this insight

Recent Analyst Ratings for $LUNG

$LUNG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director French Glendon E. Iii sold $130,400 worth of shares (20,000 units at $6.52), decreasing direct ownership by 2% to 1,091,974 units (SEC Form 4)

Director French Glendon E. Iii sold $161,800 worth of shares (20,000 units at $8.09), decreasing direct ownership by 2% to 1,111,974 units (SEC Form 4)

CHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $30,721 worth of shares (4,586 units at $6.70), decreasing direct ownership by 2% to 295,433 units (SEC Form 4)

$LUNG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

$LUNG Financials

Live finance-specific insights

Pulmonx Reports Third Quarter 2024 Financial Results

Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

Pulmonx Reports Second Quarter 2024 Financial Results

$LUNG Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

$LUNG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Pulmonx with a new price target

Pulmonx downgraded by Wells Fargo with a new price target

Craig Hallum initiated coverage on Pulmonx with a new price target

$LUNG SEC Filings

SEC Form 10-Q filed by Pulmonx Corporation

Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Pulmonx Corporation

$LUNG Market Insights

Live Market Insights

Lake Street Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $12

Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

$LUNG Leadership Updates

Live Leadership Updates

$LUNG Press Releases

Fastest customizable press release news feed in the world

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference

Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Pulmonx to Present at the Stifel 2024 Healthcare Conference

Recent Analyst Ratings for
$LUNG

$LUNG
Insider Trading

$LUNG
Insider Purchases

$LUNG
Financials

$LUNG
Large Ownership Changes

$LUNG
Analyst Ratings

$LUNG
SEC Filings

$LUNG
Market Insights

$LUNG
Leadership Updates

$LUNG
Press Releases